Tone mix
Week by week 51 weeks
Share of Travere Therapeutics, Inc. Common Stock's 195 headlines over the last 52 weeks by the model's call, and the same mix week by week.
Biggest swings in the last year
The weeks whose tone moved furthest from the 8-week average, with the story most outlets carried that week.
- Week of Mar 30, 2026 · tone -100JPMorgan Chase & Co. Cuts Travere Therapeutics (NASDAQ:TVTX) Price Target to $41.00-121
- Week of Nov 10, 2025 · tone +100Travere Therapeutics (NASDAQ:TVTX) Upgraded to "Strong-Buy" at Wall Street Zen+84
- Week of Mar 9, 2026 · tone +100Piper Sandler Increases Target Price for Travere Therapeutics (TVTX)+82
- Week of Oct 12, 2026 · tone -85FTC Seeks To Hold Martin Shkreli In Contempt For Allegedly Violating Lifetime Pharmaceutical Industry Ban-65
- Week of Nov 24, 2025 · tone +100Why IBD 50's No. 3 Stock, Travere Therapeutics, Has Doubled In 2025+63
- Week of Aug 31, 2026 · tone +98Biotech Stocks At 52-Week Highs - ATTO, HALO, IKT, TVTX, ATRC+59
Daily headline tone, last 90 sessions
Hover a session for its totals; click to pin.
Each point is the average score of the headlines about Travere Therapeutics, Inc. Common Stock in one trading session, with the 8-session average drawn through it. Sessions with no headline about the company have no point.
Tone by period
Show the table · 3 rows, 3 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Last 7 sessions | 0 | No headlines |
| Last 30 sessions | 20 | -41 |
| Last 90 sessions | 47 | +8 |
No matching rows. Clear the filter to see all records.
Every headline in the period counts equally.
Headlines on Tuesday, October 20, 2026
1 headline, average tone 0: 0 positive, 1 neutral and 0 negative. Showing all 1.
- www.dailypolitical.com · 1 outletTravere (NASDAQ: TVTX) CEO sells 243,735 shares after option exercisesNeutral
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Travere (NASDAQ: TVTX) CEO sells 243,735 shares after option exercises | www.dailypolitical.com | 1 | Neutral |
No matching rows. Clear the filter to see all records.
Headlines on Friday, October 16, 2026
1 headline, average tone -100: 0 positive, 0 neutral and 1 negative. Showing all 1.
- www.medicaldaily.com · 1 outletFTC and States Seek Contempt Finding Against Martin Shkreli Over Alleged Trading in at Least 60 Drug StocksNegative
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| FTC and States Seek Contempt Finding Against Martin Shkreli Over Alleged Trading in at Least 60 Drug Stocks | www.medicaldaily.com | 1 | Negative |
No matching rows. Clear the filter to see all records.
Headlines on Wednesday, October 14, 2026
11 headlines, average tone -84: 1 positive, 0 neutral and 10 negative. The 8 most widely carried stories are listed; the table holds all 11.
- www.zerohedge.com · 2 outletsFTC Seeks To Hold Martin Shkreli In Contempt For Allegedly Violating Lifetime Pharmaceutical Industry BanNegative
- www.wbap.com · 2 outletsFTC, Seven States Seek Contempt Finding Against Martin Shkreli Over Alleged Pharma Ban ViolationsNegative
- www.cnbc.com · 1 outletMartin Shkreli violated lifetime pharma industry ban, FTC and states say in contempt claimNegative
- www.aol.com · 1 outletMartin Shkreli violated lifetime pharma industry ban, FTC and states sayNegative
- www.inquirer.com · 1 outletMartin Shkreli should be in contempt for violating lifetime pharma ban, Pa. attorney general saysNegative
- www.theepochtimes.com · 1 outletFTC, States Accuse Martin Shkreli of Violating Lifetime Pharma BanNegative
- gizmodo.com · 1 outletPharma Bro Martin Shkreli Could Be in Big Trouble AgainNegative
- arstechnica.com · 1 outletMartin Shkreli livestreamed himself violating lifetime pharma ban, FTC saysNegative
Show the table · 11 rows, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| FTC Seeks To Hold Martin Shkreli In Contempt For Allegedly Violating Lifetime Pharmaceutical Industry Ban | www.zerohedge.com | 2 | Negative |
| FTC, Seven States Seek Contempt Finding Against Martin Shkreli Over Alleged Pharma Ban Violations | www.wbap.com | 2 | Negative |
| Martin Shkreli violated lifetime pharma industry ban, FTC and states say in contempt claim | www.cnbc.com | 1 | Negative |
| Martin Shkreli violated lifetime pharma industry ban, FTC and states say | www.aol.com | 1 | Negative |
| Martin Shkreli should be in contempt for violating lifetime pharma ban, Pa. attorney general says | www.inquirer.com | 1 | Negative |
| FTC, States Accuse Martin Shkreli of Violating Lifetime Pharma Ban | www.theepochtimes.com | 1 | Negative |
| Pharma Bro Martin Shkreli Could Be in Big Trouble Again | gizmodo.com | 1 | Negative |
| Martin Shkreli livestreamed himself violating lifetime pharma ban, FTC says | arstechnica.com | 1 | Negative |
| 'Pharma Bro' Martin Shkreli broke lifetime ban on drug industry trades, fed say | nypost.com | 1 | Negative |
| FTC Says Martin Shkreli Keeps Violating His Lifetime Pharma Ban | www.businessinsider.com | 1 | Negative |
| Travere Therapeutics, Inc. (NASDAQ:TVTX) Stock Has Consensus Price Target of $69.50 | www.tickerreport.com | 1 | Positive |
No matching rows. Clear the filter to see all records.
Headlines on Friday, September 25, 2026
1 headline, average tone +100: 1 positive, 0 neutral and 0 negative. Showing all 1.
- www.tickerreport.com · 1 outletTravere Therapeutics' (TVTX) Buy Rating Reiterated at HC WainwrightPositive
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Travere Therapeutics' (TVTX) Buy Rating Reiterated at HC Wainwright | www.tickerreport.com | 1 | Positive |
No matching rows. Clear the filter to see all records.
Headlines on Monday, September 21, 2026
1 headline, average tone +98: 1 positive, 0 neutral and 0 negative. Showing all 1.
- www.themarketsdaily.com · 1 outletTravere Therapeutics, Inc. (NASDAQ:TVTX) Receives $68.00 Consensus Price Target from BrokeragesPositive
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Travere Therapeutics, Inc. (NASDAQ:TVTX) Receives $68.00 Consensus Price Target from Brokerages | www.themarketsdaily.com | 1 | Positive |
No matching rows. Clear the filter to see all records.
How the score works
A headline's tone is not a forecast of the share price. Read the headlines themselves before acting on an average.
Which headlines count
Headlines come from the GDELT global news feed from 2019-09-23 on. A headline counts only when a model judges it to be about Travere Therapeutics, Inc. Common Stock, not a passing mention.
How each headline is scored
The model calls each headline positive, neutral or negative news for the company. A period's tone is the share of positive minus negative headlines, from -100 (all negative) to +100 (all positive).
When a headline counts
Headlines published by 9:15 a.m. New York time belong to that day's session. Later and weekend headlines move to the next trading session.
Repeated stories
When several outlets carry the same headline, it counts once per session.